Logotype for Lifeward Ltd

Lifeward (LFWD) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Lifeward Ltd

Q3 2026 earnings summary

13 Nov, 2026

Executive summary

  • Q3 revenue fell 12% YoY to $5.428M as lower ReWalk sales outweighed AlterG growth; gross margin declined to 27.4% and net loss widened to $5.052M.

  • Nine-month revenue was $15.974M, down 6% YoY, while net loss increased to $27.364M; a $4.947M acquired IPR&D charge and financing-related fair-value changes affected results.

  • AlterG grew double digits as ReWalk sales declined amid the transition from direct sales to channel partners, affecting near-term sales timing.

  • September 30 cash was $4.548M, and $16.064M of nine-month operating cash outflow contributed to substantial doubt about the ability to continue as a going concern without additional funding or spending cuts.

Financial highlights

  • Q3 revenue was $5.428M vs. $6.195M YoY; nine-month revenue was $15.974M vs. $16.953M.

  • Q3 gross profit was $1.487M vs. $2.707M; nine-month gross profit was $5.538M vs. $7.340M.

  • Q3 operating loss was $5.970M vs. $3.140M; nine-month operating loss was $20.461M vs. $14.556M.

  • Q3 net loss was $5.052M vs. $3.170M; adjusted net loss was $5.5M. Nine-month net loss was $27.364M vs. $14.566M.

  • Q3 basic and diluted loss per share was $1.32 vs. $2.37; nine-month loss per share was $9.91 vs. $13.87.

Outlook and guidance

  • Existing cash resources are not expected to fund planned operations for the next 12 months; potential responses include additional debt or equity, strategic arrangements and cost reductions.

  • If financing is unavailable, planned liquidity measures include prioritizing R&D, delaying some product development and cutting discretionary expenses.

  • Growth priorities include ReWalk reimbursement and channel partnerships, higher AlterG shipments, product improvements, ORMD-0801 clinical development and Skelable technology development.

  • Gross profit and margin are expected to improve over time subject to higher volumes, fixed-cost absorption and operational efficiencies; AI-enabled rehabilitation capabilities are also under development.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Lifeward